The pharmacogenetics of antidepressant treatments for depressive disorders

Min-Soo Lee

doi:10.1002/ddr.20020

The pharmacogenetics of antidepressant treatments for depressive disorders

Min-Soo Lee

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

Abstract

Pharmacological treatments for depressive disorder vary between individuals, with 30-40% of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold-standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G-protein β subunit, and the norepinephrine transporter.

Original language	English
Pages (from-to)	170-178
Number of pages	9
Journal	Drug Development Research
Volume	65
Issue number	3
DOIs	https://doi.org/10.1002/ddr.20020
Publication status	Published - 2005 Jul 1

Keywords

Depression
Norepinephrine transporter
Pharmacogenetics
Serotonin transporter
Tryptophan hydroxylase

ASJC Scopus subject areas

Drug Discovery
Organic Chemistry
Pharmacology

Access to Document

10.1002/ddr.20020

Cite this

@article{7e1757c9547042bca5d6aa6072f4da8b,

title = "The pharmacogenetics of antidepressant treatments for depressive disorders",

abstract = "Pharmacological treatments for depressive disorder vary between individuals, with 30-40% of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold-standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G-protein β subunit, and the norepinephrine transporter.",

keywords = "Depression, Norepinephrine transporter, Pharmacogenetics, Serotonin transporter, Tryptophan hydroxylase",

author = "Min-Soo Lee",

year = "2005",

month = jul,

day = "1",

doi = "10.1002/ddr.20020",

language = "English",

volume = "65",

pages = "170--178",

journal = "Drug Development Research",

issn = "0272-4391",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - The pharmacogenetics of antidepressant treatments for depressive disorders

AU - Lee, Min-Soo

PY - 2005/7/1

Y1 - 2005/7/1

N2 - Pharmacological treatments for depressive disorder vary between individuals, with 30-40% of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold-standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G-protein β subunit, and the norepinephrine transporter.

AB - Pharmacological treatments for depressive disorder vary between individuals, with 30-40% of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold-standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G-protein β subunit, and the norepinephrine transporter.

KW - Depression

KW - Norepinephrine transporter

KW - Pharmacogenetics

KW - Serotonin transporter

KW - Tryptophan hydroxylase

UR - http://www.scopus.com/inward/record.url?scp=28444436223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444436223&partnerID=8YFLogxK

U2 - 10.1002/ddr.20020

DO - 10.1002/ddr.20020

M3 - Review article

AN - SCOPUS:28444436223

SN - 0272-4391

VL - 65

SP - 170

EP - 178

JO - Drug Development Research

JF - Drug Development Research

IS - 3

ER -

The pharmacogenetics of antidepressant treatments for depressive disorders

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this